WallStreetZenWallStreetZen

NASDAQ: REGN
Regeneron Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for REGN

Based on 13 analysts offering 12 month price targets for Regeneron Pharmaceuticals Inc.
Min Forecast
$800.00-18.6%
Avg Forecast
$963.23-1.99%
Max Forecast
$1,184.00+20.47%

Should I buy or sell REGN stock?

Based on 13 analysts offering ratings for Regeneron Pharmaceuticals Inc.
Strong Buy
Strong Buy
6 analysts 46.15%
Buy
4 analysts 30.77%
Hold
3 analysts 23.08%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their REGN stock forecasts and price targets.

REGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-27
lockedlocked$00.00+00.00%2024-02-06
lockedlocked$00.00+00.00%2024-02-05
lockedlocked$00.00+00.00%2024-01-23Find Out Why
lockedlocked$00.00+00.00%2023-12-18
TD Cowen
Bottom 5%
5
BuyMaintains$1,000.00+1.75%2023-12-06
Jefferies
Top 23%
78
Strong BuyMaintains$937.00-4.66%2023-11-28
Deutsche Bank
Top 32%
69
HoldInitiates Coverage On$800.00-18.60%2023-11-09
Piper Sandler
Top 11%
90
Strong BuyMaintains$895.00-8.94%2023-11-03
Morgan Stanley
Top 42%
59
Strong BuyMaintains$914.00-7.00%2023-11-03

1 of 2

Forecast return on equity

Is REGN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.11%

Forecast return on assets

Is REGN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

REGN revenue forecast

What is REGN's revenue in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$14.0B+6.69%
Avg 2 year Forecast
$15.1B+15.09%
Avg 3 year Forecast
$16.4B+25.17%
REGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

REGN earnings growth forecast

How is REGN forecast to perform vs Biotechnology companies and vs the US market?
Company
4.84%
Industry
6.69%
Market
22.32%
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
REGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

REGN revenue growth forecast

How is REGN forecast to perform vs Biotechnology companies and vs the US market?
Company
7.69%
Industry
45.89%
Market
10.82%
REGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
REGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

REGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
REGN$982.82$963.23-1.99%Strong Buy
VRTX$432.76$441.79+2.09%Buy
MRNA$95.06$129.29+36.00%Buy
ARGX$393.49$505.57+28.48%Strong Buy
BNTX$90.94$118.00+29.76%Hold

Regeneron Pharmaceuticals Stock Forecast FAQ

Is Regeneron Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 13 Wall Street analysts covering (NASDAQ: REGN) stock is to Strong Buy REGN stock.

Out of 13 analysts, 6 (46.15%) are recommending REGN as a Strong Buy, 4 (30.77%) are recommending REGN as a Buy, 3 (23.08%) are recommending REGN as a Hold, 0 (0%) are recommending REGN as a Sell, and 0 (0%) are recommending REGN as a Strong Sell.

If you're new to stock investing, here's how to buy Regeneron Pharmaceuticals stock.

What is REGN's revenue growth forecast for 2024-2026?

(NASDAQ: REGN) Regeneron Pharmaceuticals's forecast annual revenue growth rate of 7.69% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.82%.

Regeneron Pharmaceuticals's revenue in 2024 is $13,117,200,000.On average, 8 Wall Street analysts forecast REGN's revenue for 2024 to be $1,536,017,960,957, with the lowest REGN revenue forecast at $1,473,992,501,384, and the highest REGN revenue forecast at $1,617,307,511,372. On average, 8 Wall Street analysts forecast REGN's revenue for 2025 to be $1,657,040,439,629, with the lowest REGN revenue forecast at $1,531,507,734,888, and the highest REGN revenue forecast at $1,731,760,630,807.

In 2026, REGN is forecast to generate $1,802,113,286,382 in revenue, with the lowest revenue forecast at $1,640,720,821,408 and the highest revenue forecast at $1,885,830,111,366.

What is REGN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: REGN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is REGN's Price Target?

According to 13 Wall Street analysts that have issued a 1 year REGN price target, the average REGN price target is $963.23, with the highest REGN stock price forecast at $1,184.00 and the lowest REGN stock price forecast at $800.00.

On average, Wall Street analysts predict that Regeneron Pharmaceuticals's share price could fall to $963.23 by Feb 27, 2025. The average Regeneron Pharmaceuticals stock price prediction forecasts a potential downside of 1.99% from the current REGN share price of $982.82.

What is REGN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: REGN) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.